ZymIQ Technology – Advancing Enzyme-Based Innovations for Health and Beauty

“Our focus is on delivering safe, effective and innovative solutions that offer alternatives to traditional treatments, particularly in combating antibiotic resistance.”

In a world facing evolving health challenges, ZymIQ is committed to making a meaningful impact through smart enzyme technology and phage research. At the core of ZymIQ’s mission is a deep commitment to addressing antibiotic resistance, one of today’s critical health challenges. Leveraging advanced scientific research, ZymIQ is working to develop enzyme-based antimicrobials, contributing to the ongoing fight against this growing threat.

ZymIQ’s resources include two powerful enzyme technology platforms that offer targeted antimicrobial solutions. The Combat platform eliminates specific bacteria, including antibiotic-resistant strains, ensuring rapid and effective treatment. Meanwhile, the Prevent platform reduces microbial adhesion, forming a protective barrier to support a healthy microbiome and prevent infections.

In an exclusive interview with CIO Bulletin, Michael Edelborg Christensen, CEO of ZymIQ Technology, shared insights into how he and his team of experts are staying one step ahead in both research and innovation to contribute to current and future health trends.

Interview Highlights

What circumstances or events led to the founding of ZymIQ Technology?

Dr. Mats Clarsund, an expert in drug and medical device development with a focus on enzymes, and I share a belief in the potential of enzymes in health products. Drawing from our successful collaboration in enzyme-based products, we identified key areas for improvement, particularly in enhancing stability and effectiveness. Not least, we saw the potential to develop therapeutics that could combat both existing and emerging microbial infections, thus replacing antibiotic treatments for humans and animals. According to the WHO, antibiotic resistance poses a major threat to global health, and at ZymIQ, we aim to address this challenge through smart enzyme research and technology.

ZymIQ was established in 2020 with the backing of a dedicated team of scientists, experts, and entrepreneurs. The company is headquartered in Medicon Village, Sweden, with additional offices in Virginia, USA, Singapore, and Malaysia. We are continually working to advance our brands and research platforms, focusing on developing new and innovative cosmetic and health products for humans and animals.

What are the scientific and technological advancements that underpin ZymIQ’s development of antimicrobial solutions?

In response to health challenges like rising drug resistance and emerging microbial infections, ZymIQ is committed to developing enzyme-based solutions that harness the unique catalytic power of enzymes. Enzymes can target specific pathogens and work in synergy with the body’s natural defense system, offering a safer and potentially more effective alternative to synthetic antibiotics.

ZymIQ’s Combat platform eliminates harmful bacteria with high precision, including resistant strains, while the Prevent platform creates a protective barrier to inhibit future bacterial adhesion. Combined, they could deliver immediate antimicrobial action and sustained protection, supporting both infection control and long-term microbiome health.

Additionally, ZymIQ has acquired SPL, a phage-based vaccine designed to activate the immune system to target staphylococcal infections in both humans and animals. This approach provides targeted treatment while preserving beneficial bacteria and reducing dependence on antibiotic therapies. Plans are underway to reintroduce SPL to the US veterinarian market for dogs.

What strategies does ZymIQ employ to ensure the successful global market penetration of its products?

ZymIQ takes a broad approach to global market penetration. Our data-driven approach ensures adherence to compliance requirements and the delivery of high-quality products, providing us with a competitive edge. Understanding customer preferences and local regulations is crucial to our operations.

Additionally, we form strategic partnerships with companies, universities, and research institutions to access new technologies, expertise, and markets. Our strong collaborations enable us to accelerate product development and market access.

How does ZymIQ’s approach to developing enzyme-based therapeutics and cosmetics differ from traditional products?

ZymIQ’s approach to developing enzyme-based therapeutics and cosmetics focuses on precision and microbiome-friendly solutions, setting it apart from traditional products. Unlike conventional antimicrobials or cosmetics that often disrupt the skin or body’s natural balance, ZymIQ’s enzymes target harmful pathogens specifically, minimizing side effects. This approach promotes a healthier microbiome, supporting long-term wellness rather than temporary solutions.

In what ways does ZymIQ prioritize sustainability and ethical practices?

ZymIQ integrates sustainability and ethical practices from product development to clinical studies. Our enzyme-based formulations are biodegradable and eco-friendly, avoiding harmful chemicals. ZymIQ prioritizes ethical sourcing and cruelty-free standards, ensuring transparency. In clinical studies, we uphold rigorous ethical standards, prioritizing participant safety, informed consent, and compliance with global regulations.

What new endeavors is ZymIQ currently undertaking?

ZymIQ is pushing the boundaries of enzyme-based health and wellness solutions with exciting new developments. Our recently opened lab is enabling cutting-edge research into enzyme formulations, resulting in several promising products currently in the pipeline.

Within the DentaPrev brand, we are soon introducing an innovative enzyme lozenge that provides effective, on-the-go oral care, offering results comparable to toothbrushing by helping prevent plaque, tartar, and bad breath.

Additionally, we have expanded our presence in animal healthcare with the U.S. launch of Kalzyme, offering enzyme-based dental and dermal care for dogs and cats. These products are also available in Sweden and Asia.

In collaboration with Fjör, a skincare brand, we’ve recently introduced a new body moisturizer, enhancing our portfolio in the skincare space. We are honored to have our innovations recognized by leading publications such as The New York Times, British Vogue, Esquire Magazine, and Wallpaper.

Finally, we are actively pursuing a Nasdaq IPO. Our focus remains on market expansion and organizational strengthening, with plans to allocate funds to expedite the final-stage development and regulatory approval processes for our pipeline products.

Is there anything you would like to add before we wrap up?

We’re grateful for recent recognitions, including the APAC Insider Singapore Business Award for our enzyme research and Fjör’s enzyme moisturizer winning an Oscar Beauty Award. Additionally, we’re thrilled to announce that one of our projects has received funding from Vinnova, Swedens Innovation Agency, supporting our early-phase research and innovation. As we continue to develop enzyme technology, we remain dedicated to contributing to the future of health and biotechnology. We look forward to sharing our progress and the new possibilities we discover along the way.

Meet ZymIQ Technology’s Leadership Team

ZymIQ Technology’s leadership team comprises seasoned professionals with diverse expertise and a proven track record of success. Here’s a closer look at the key members:

Michael Edelborg Christensen, CEO: A globally-focused entrepreneur, Michael brings valuable international CEO experience to the table. With a history of enhancing shareholding value in both private and public companies, he notably led a life science company through its successful IPO, resulting in a remarkable tenfold increase in share value within a short timeframe. Under his leadership, that company’s Market Cap exceeded $100 million.

Dr. Mats Clarsund, CTO: Mats is an expert in market and scientific-oriented drug and medical device development. His extensive experience spans from early drug discovery to the successful introduction and expansion of medical device products.

Erik Rexo, CRO: Erik is a highly experienced revenue growth strategist, Go-to-Market expert, and entrepreneur. With a striking track record of launching over 120 new products, services, and innovations across Fortune 100 companies, he now leads ZymIQ’s product commercialization efforts and oversees distribution in North America.

“ZymIQ has acquired SPL, a phage-based vaccine that activates the immune system to target staphylococcal infections in both humans and animals, offering precise treatments without harming beneficial bacteria. This significantly reduces reliance on antibiotic therapy.”